Inactive Instrument

Opko Health Inc. Nyse

Equities

US68375N1037

Healthcare Facilities & Services

End-of-day quote Nyse Other stock markets
- ^USD	-

Mar. 28	Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	MT
Mar. 20	Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	CI

OPKO Health : to Present at the Jefferies 2015 Healthcare Conference

May 27, 2015 at 10:55 am EDT

OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies 2015 Healthcare Conference on Wednesday, June 3, 2015 at 4:00 PM EDT in New York City.

The presentation will be webcast on the OPKO Investor Relations page of the corporate website at www.opko.com. To access the live webcast please log on to the OPKO site approximately fifteen minutes before the presentation to register and download any necessary audio software. The audio presentation will be available at this link for a limited time after the live presentation.

About OPKO Health, Inc.

OPKO is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies. For more information, visit http://www.opko.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150527006092/en/

Latest news about Opko Health Inc.

Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	Mar. 28	MT
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	CI
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing	Mar. 14	MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing	Mar. 13	MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing	Mar. 12	MT
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating	Feb. 28	MT
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M	Feb. 27	MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Opko Health Insider Bought Shares Worth $991,700, According to a Recent SEC Filing	Feb. 21	MT
HealthSnap, Inc. announced that it has received $24.999999 million in funding from a group of investors	Feb. 20	CI
OPKO Health, Inc. Announces the Cessation of Alexis Borisy as Member of the Board of Directors and Member of Compensation Committee of the Board	Feb. 09	CI
NextPlat Preparing to Launch Opko Health Store on Alibaba's Tmall Global Platform	Feb. 05	MT
Opko Health Insider Bought Shares Worth $488,650, According to a Recent SEC Filing	Jan. 19	MT
Opko Health Insider Bought Shares Worth $386,200, According to a Recent SEC Filing	Jan. 18	MT
Opko Health Insider Bought Shares Worth $954,300, According to a Recent SEC Filing	Jan. 16	MT
Opko Health Insider Bought Shares Worth $480,379, According to a Recent SEC Filing	Jan. 11	MT
Transcript : OPKO Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
OPKO Health Closes Private Offering of $230 Million Convertible Notes Due 2029	Jan. 09	MT
Opko Health Insider Bought Shares Worth $1,344,600, According to a Recent SEC Filing	Jan. 08	MT
Opko Health Insider Bought Shares Worth $514,093, According to a Recent SEC Filing	Jan. 05	MT
OPKO Health Prices $200 Million Convertible Senior Notes Offering	Jan. 05	MT
Top Midday Decliners	Jan. 04	MT
Sector Update: Health Care Stocks Advance Pre-Bell Thursday	Jan. 04	MT

Chart Opko Health Inc.

Duration

Period

More charts

Company Profile

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.

Sector

Healthcare Facilities & Services

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
SONIC HEALTHCARE LIMITED	-18.55%	8.02B
RADNET, INC.	+36.93%	3.51B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-26.72%	2.97B
SYNLAB AG	-7.36%	2.48B
DR. LAL PATHLABS LIMITED	-14.75%	2.23B
NEOGENOMICS, INC.	-14.89%	1.76B
FLEURY S.A.	-23.12%	1.44B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-39.19%	1.25B
ADICON HOLDINGS LIMITED	-10.89%	1.11B

Medical & Diagnostic Laboratories